Physician profile
Stacey Sumner
NPI 1063449817
$1,010.29
in general payments reported to CMS, 2019-2025
11 companies · $324 in 2025
The $324 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $448 · 2020: $115 · 2023: $38.93 · 2024: $84.85 · 2025: $324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $448.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $447.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $341.94 | 2019-2024 | Total30 |
| Glaukos Corporation | $320.07 | 2019-2025 | Photrexa Viscous and Photrexa, Idosetr |
| Johnson & Johnson Vision Care, INC. | $70.38 | 2019-2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $69.18 | 2019-2020 | |
| Abb Con-Cise Optical Group LLC | $47.97 | 2019 | |
| Novartis Pharmaceuticals Corporation | $42.91 | 2019-2020 | |
| Coopervision INC. | $37.37 | 2020-2025 | Myday Contact Lens |
| Shire North American Group INC | $26.54 | 2019 | |
| Visioneering Technologies, INC. | $20.34 | 2019 | |
| Bausch & Lomb Americas INC. | $19.77 | 2023 | Infuse |
| Eyevance Pharmaceuticals LLC | $13.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Sumner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.